interesting post

Interesting post by Betasplen 1 on Yahoo finance:

"Now that BARDA is gone, let's say revenue stays at $9M, without accounting for any growth. R&D was $4.5M last quarter. G&A was $2.3M. Say expenses fall 30% because they don't have to move heaven and earth to appease BARDA anymore. Then net profits per quarter will be $4.2M. Annualized, that is $16.8M. PE of 10 is $168MM market cap + $80M in cash or $248MM market cap is $7/share. Voila - that is still the analyst target. And this is not accounting for the BARDA settlement or any new partnerships with GSK. This will suddenly jump one day and run."